Novagali launches dry eye treatment Cationorm

Article

Cationorm, a cationic emulsion to treat dry eye, has been launched in France by Novagali Pharma.

Cationorm, a cationic emulsion to treat dry eye, has been launched in France by Novagali Pharma.

The emulsion, which uses Novasorb technology, acts on the different levels of the tear film. Novasorb, a proprietary platform of Novagali's, uses the electrostatic attraction between the positively charged emulsion and the negatively charged cells of the ocular surface, including cornea and conjunctiva.

Cationorm combines lubricating and hydrating properties to replenish the tear film lipid layer and prevent tear evaporation. Clinical studies have proven the efficacy of Cationorm in treating dry eye symptoms, and it is associated with increased tolerance and comfort.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.